Becton Dickinson And Company NYSE:BDX Price, Chart, News & Insight

BD Advances GalaFLEX LITE Trial for Breast Revision Surgery

Becton, Dickinson and Company (NYSE: BDX) announced a key clinical milestone for its GalaFLEX LITE Scaffold, strengthening its push into advanced tissue regeneration.

The STANCE trial has now treated 274 patients across 33 U.S. sites, surpassing 50% of its maximum planned enrollment and triggering the study’s first interim analysis.

The randomized trial is evaluating whether GalaFLEX LITE can reduce recurrence of capsular contracture and implant malposition following breast revision surgery compared with conventional treatment.

Capsular contracture is one of the most common complications of implant-based breast surgery, with reported incidence of 10%–20% and recurrence after conventional revision procedures potentially reaching 54%.

The study is intended to generate clinical evidence supporting an FDA Premarket Approval application for a breast indication. GalaFLEX LITE uses BD’s bioabsorbable P4HB technology, which has more than a decade of clinical use in soft-tissue support applications.

For BD, a successful trial could expand GalaFLEX LITE into a sizable new indication within plastic and reconstructive surgery and strengthen the company's position in advanced tissue regeneration.

💬

Global Finance News 08-27-26

BD Completes Enrollment in Landmark Phasix Mesh Hernia Prevention Trial

Becton, Dickinson and Company (NYSE: BDX) has completed patient enrollment in its PREVENT clinical trial evaluating Phasix Mesh for the prevention of incisional hernias following abdominal surgery.

The randomized study enrolled 477 patients across 32 sites in the U.S. and Europe. According to BD, it is the first large-scale randomized trial evaluating prophylactic incisional hernia prevention using a resorbable mesh.

The trial targets patients at high risk of developing incisional hernias following elective open midline abdominal surgery. The milestone supports BD's strategy to expand its advanced tissue regeneration technologies into new clinical applications.

Patients will be followed through the trial's primary endpoint at 24 months, with additional follow-up planned for up to five years to assess safety and clinical outcomes.

If the study produces supportive results, BD expects the data to form part of a planned FDA submission seeking authorization for Phasix Mesh in this new indication.

The program could represent an important expansion opportunity for BD's surgical portfolio, as the company noted that no products are currently approved specifically for preventing incisional hernias following abdominal surgery.

💬

WS Investor 08-12-26

BD Jumps 6% as Clean Quarter, EPS Raise, and Post-Spin Clarity Win Over Investors

Franklin Lakes, May 7, 2026 — Shares in Becton, Dickinson and Company rose around 6% today after the medical technology company delivered a second fiscal quarter that beat expectations across revenue, margins, and earnings, then raised its full-year adjusted EPS guidance — a combination that gave investors the reassurance they needed following a period of significant corporate restructuring.

BD reported Q2 fiscal 2026 revenues of $4.714 billion, up 5.2% year-over-year or 2.6% on a foreign currency neutral basis. Adjusted diluted EPS came in at $2.90, up 3.9% from $2.79 in the prior year period and ahead of internal expectations. The GAAP EPS was a loss of $0.13, reflecting charges tied to the company's recently completed spin-off of its Biosciences and Diagnostic Solutions business, which was combined with Waters Corporation in February 2026. Investors have largely set aside GAAP noise in the post-spin period and are focused on the underlying continuing operations.

The breadth of the performance impressed. CEO Tom Polen noted that more than 90% of the business delivered mid-single-digit growth, with the Interventional segment leading the way at 7.3% reported growth and 5.3% on a currency neutral basis. Connected Care grew 4.9% and Medical Essentials 4.7%. BioPharma Systems was the one soft spot, growing just 2.5% reported and contracting slightly on a currency neutral basis.

The capital allocation moves added to the positive sentiment. BD executed a $2 billion accelerated share repurchase program and retired $2.1 billion of debt during the quarter — a substantial deleveraging effort that signals management's confidence in the business's cash generation and strengthens the balance sheet profile of the leaner, post-spin company.

Full-year adjusted diluted EPS guidance was raised to $12.52 to $12.72, up from the prior range of $12.35 to $12.65, while revenue growth guidance was reaffirmed. For a company still in the early stages of repositioning after a major strategic separation, the combination of execution, capital discipline, and raised guidance was enough to send the stock meaningfully higher.

💬

European Investor 05-07-26

Becton, Dickinson and Company announced CE Mark approval for its Liverty™ TIPS Stent Graft, introducing a next-generation treatment option for patients with portal hypertension across the European Union.

The device is designed to support patients with advanced liver disease, including cirrhosis-related complications, by improving blood flow through transjugular intrahepatic portosystemic shunt (TIPS) procedures. Its adjustable diameter (6–10 mm) allows physicians to tailor treatment to individual patient needs, enhancing precision and potential long-term outcomes.

Clinical data from the ARCH trial demonstrated the device’s safety and effectiveness and will be presented at the Society of Interventional Radiology’s 2026 annual meeting. The stent graft features a flexible, self-expanding structure and advanced materials aimed at improving placement accuracy and durability.

The approval expands treatment options in Europe for a condition affecting millions globally, while the device remains under investigational use in the United States.
PRNewswire

💬

WS Investor 04-08-26

Becton, Dickinson and Company announced the launch of its HemoSphere Stream Module, a new solution enabling continuous, noninvasive blood pressure monitoring for patients.

The device provides real-time, beat-to-beat arterial waveform data using a finger cuff, allowing clinicians to track blood pressure changes continuously rather than relying on intermittent measurements. It integrates with existing bedside monitors and is designed to improve detection of critical changes during and after procedures.

BD said the technology helps address gaps in patient monitoring, particularly in surgical and critical care settings, supporting earlier intervention and improved patient safety.

The launch reflects growing demand for noninvasive, continuous monitoring solutions in healthcare.
PRNewswire

💬

WS Investor 04-07-26

Becton, Dickinson and Company announced the European launch of its AI-enabled medication management solutions, including the BD Pyxis Pro Dispensing System and the BD Incada Connected Care Platform.

The new system combines automation and AI-driven analytics to improve medication storage, tracking, and access at the point of care, helping hospitals enhance efficiency, reduce waste, and strengthen patient safety. Features include RFID-based access, barcode scanning, and real-time inventory visibility.

Built on cloud infrastructure, the platform enables healthcare providers to analyze medication usage patterns and optimize workflows across large networks of connected devices. BD said the solution will support digital sovereignty requirements in Europe while maintaining high performance and security standards.

The rollout marks an expansion of BD’s connected care capabilities, aiming to modernize hospital pharmacy operations and improve clinical outcomes across the region.
PRNewswire

💬

Global Finance News 04-03-26

Becton, Dickinson and Company (NYSE: BDX) has received U.S. FDA 510(k) clearance for Surgiphor™ 1000mL, the first and only 1,000 mL antimicrobial irrigation system designed specifically for powered lavage.

The terminally sterile, ready-to-use PVP-I solution is engineered to mechanically remove debris and microorganisms during wound irrigation, eliminating the need for manual mixing in the operating room. The system is compatible with commonly used powered lavage devices and includes adapters, a Y-connector for saline switching, and a collapsible bottle to support optimized flow and handling.

BD said the larger-volume configuration expands its Surgiphor™ portfolio, offering both manual and powered irrigation options to improve surgical efficiency, consistency, and patient safety.
PRNewswire

💬

European Investor 03-03-26

Becton, Dickinson and Company (NYSE: BDX) announced the launch of the BD Vacutainer® Urine Complete Cup Kit, a three-tube urine collection system designed to preserve specimen quality and expand testing capabilities from a single sample.

The kit includes a sterile cup with integrated transfer device, culture and sensitivity tube, urinalysis tube, discard tube and castile wipe. The added third tube allows broader testing without manual transfers or repeat collections, helping reduce contamination risk and improve workflow efficiency.

BD said the system aims to enhance diagnostic accuracy, support automated lab workflows and reduce inappropriate treatments linked to contaminated urine cultures.

Source: PR Newswire

💬

The Investor 02-23-26

BD (Becton, Dickinson and Company) announced the completion of the spin-off of its Biosciences & Diagnostic Solutions business and its combination with Waters Corporation, finalizing a transaction that values the business at approximately $18.8 billion. Under the deal, BD shareholders received about 0.135 Waters shares per BD share and BD received $4 billion in cash, with BD shareholders owning roughly 39.2% of the combined company on a fully diluted basis. BD plans to use $2 billion of the proceeds for accelerated share repurchases and $2 billion for debt reduction, positioning the company as a more focused pure-play MedTech firm. The transaction marks the completion of BD’s 2025 strategy and is intended to support long-term growth through innovation, connected care, and operational excellence.

Source: PRNewswire, February 9, 2026

💬

Global Finance News 02-09-26

BD (Becton, Dickinson and Company) reported first-quarter fiscal 2026 revenue of $5.3 billion, up 1.6% as reported and 0.4% on a foreign-exchange neutral basis, with New BD revenue growing 2.5% FXN. GAAP diluted EPS was $1.34, while adjusted diluted EPS reached $2.91 for the quarter ended December 31, 2025.

The company said performance exceeded expectations, supported by disciplined execution and broad-based growth across key end markets. BD also confirmed that the combination of its Biosciences and Diagnostic Solutions business with Waters Corporation is expected to close today, marking a strategic pivot toward “New BD.” Management reaffirmed full-year fiscal 2026 revenue growth guidance and introduced adjusted diluted EPS guidance for New BD.

During the quarter, BD announced several strategic and product milestones, including collaborations to expand hazardous drug contamination testing, the first U.S. implementation of BD Alaris EMR Infusion Interoperability with MEDITECH, and a $110 million investment to expand U.S. production of BD Neopak glass prefillable syringes to support biologics and GLP-1 drug delivery. Additional highlights included regulatory clearance for new interventional products, portfolio expansions in continence care and surgical systems, and progress in clinical studies for vascular devices.

💬

Global Finance News 02-09-26

NYSE:BDXFollow

NYSE:BDX